|
萩原 將太郎
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position |
|
| Article types | Original article |
| Language | English |
| Peer review | Peer reviewed |
| Title | Status and cost analysis of antimicrobial treatment of terminally ill patients with hematological malignancy in an acute hospital. |
| Journal | Formal name：Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy Abbreviation：J Infect Chemother ISSN code：14377780/1341321X |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | 26(12),pp.1288-1293 |
| Author and coauthor | Chiba Miyuki†, Negishi Miyako, Miyagawa Sanae, Suzuki Satoru, Sasai Emiko, Sugai Kazunori, Hagiwara Shotaro* |
| Authorship | Last author,Corresponding author |
| Publication date | 2020/12 |
| Summary | OBJECTIVE:Terminally ill patients with hematological malignancy tend to be treated aggressively. We aimed to clarify the status and costs of antimicrobial treatment of patients dying with hematological malignancies.METHODS:This retrospective study was conducted in a Japanese acute hospital between September 2010 and August 2015. A total of 141 patients who stayed for 14 days or longer and died in the hospital were investigated.RESULTS:The median patient age was 67 years (range, 22-93). Most patients were treated with antibacterial, antifungal, and antiviral agents (98%, 75%, and 27% of the patients, respectively) in the last 14 days of their lives. The frequency of antibiotics used in the last 7 days did not differ from that of the week before. The median cost of antimicrobials was 245,000 JPY (2227 USD), which reflected 16% of the total medical costs spent over the last 14 days. A subgroup analysis of the patients according to care policy (aggressive care policy (A) and palliative care policy (P), respectively) showed that the total medical cost in group P in the last 7 days decreased from that of the preceding week; however, the cost of antimicrobials did not lessen even in the last 7 days.CONCLUSIONS:Most patients dying with hematological malignancy were treated with a broad spectrum of antimicrobials. It appeared to be difficult to reduce, let alone discontinue antimicrobial treatment even in patients treated according to the palliative care policy. The optimal use of antibiotics for hematological patients in their end-of-life should be discussed. |
| DOI | 10.1016/j.jiac.2020.07.017 |
| PMID | 32830046 |